Affiliation:
1. Blokhin National Medical Research Center of Oncology
Abstract
Cervical cancer is one of the most common malignant tumors in Russia. Despite the high cure rates with local treatment approaches (eg, surgery or radiothearapy) at early stages of the disease, metastatic cervical cancer portends an unfavorable prognosis. The incidence and mortality rates over the last 10 years remain at a consistently high level. The backbone of treatment for metastatic cervical cancer is platinum-based combinations – the cytototic combination of paclitaxel and cisplatin (or carboplatin) being a standard-of-care treatment for patients with metastatic disease. However, chemotherapy alone failed to achieve satisfactory long-term treatment outcomes – the expected life expectancy with chemotherapeutic drugs rarely exceeds 12 months. One of the most fruitful directions in the treatment of metastatic cervical cancer to date is immunotherapy – in particular, pembrolizumab, a PD-1 pathway inhibitor – one of the key checkpoints of the immune response control. This review article highlights historical and recent achievements in metastatic cervical cancer treatment. It highlights the development of anticancer medications for advanced or metastatic cervical cancer, including targeted antiangiogenic therapy, immunotherapy, and the latest research data on the effectiveness of combining these classes of drugs with standard cytotoxic chemotherapy to achieve the best treatment outcomes.
Reference32 articles.
1. Kaprin AD, Starinskii VV, Shakhzadova AO (red.). Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2022 godu. M.: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii; 2023. 239 s. Rezhim dostupa: https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022-el.versiya_compressed.pdf.
2. Kaprin AD, Starinskii VV, Shakhzadova AO (red.). Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). M.: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii; 2022. 252 s. Rezhim dostupa: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-vrossii-v-2021-g_zabolevaemost-i-smertnost.pdf.
3. Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes. Clin Exp Metastasis. 2020;37(1):107–113. https://doi.org/10.1007/s10585-019-10007-0.
4. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(15):3113–3119. https://doi.org/10.1200/JCO.2004.04.17.
5. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009;27(28):4649–4655. https://doi.org/10.1200/JCO.2009.21.8909.